* Q4 numbers largely in-line with expectations * Large move-out in Q1 weighs on outlook * 2026e P/CE...
We expect continued good growth in Q4 and fairly flat margin development q/q.
Redeye updates its estimates and valuation following Navigo releasing its Q4 2025 report.
Redeye provides an update following CLS’s Q4 2025 report.
The share price has come up by 24% over the past three months.
Redeye is positive on the new CPT III codes for Paxman’s CIPN device.
Redeye retains its positive view of Formpipe following a mixed Q4 report, which showed strong profit...
Redeye makes some downward adjustments to our near-term forecasts as order bookings have been slow l...
* Q4 Paper EBIT of ~PLN 13.2m * Lower wood costs ahead, but markets still challenging * Fair value r...
* Adj. EBITA margin up 1.7pp as sales grew 15% ex. M&A * Likely to exceed conservative guidance in '...
* FY guidance as expected, but Q1 comments ahead of plan * '26e adj.
Redeye updates its estimates following Safeture’s Q4 2025 results, which showed continued sequential...
Systemair väntas leverera ett starkt tredje kvartal med fortsatt organisk tillväxt och stigande marg...
Kursnedgången i flygteknikbolaget har pressat värderingen till attraktiva nivåer.
Omsättningen föll till 7,8 MEUR (-17%) p.g.a. omförhandlade B2B-avtal, men bruttomarginalen steg kra...
Redeye views Ferroamp’s SEK35m financing package from SEB and Almi as a constructive step in strengt...
Redeye comments on Oncopeptides’ Q4 report. Sales declined by 8% versus Q3 2025 when growth was expe...
Cereno Scientific’s recent capital markets day (CMD) centered on CS1’s progression from early clinic...
Fastighetsbolaget Trianons förvaltningsresultat per aktie ökade med 27 procent under 2025 jämfört me...
Den amerikanska delen av Active Biotechs myelofibros-projekt har fått tillstånd att starta rekryteri...
